Tanezumab: A future option for pain control in knee osteoarthritis ?
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
N Engl J Med. 2010 Oct 14;363(16):1521-31.450 patients (age range 40 to 75) with knee osteoarthritis were randomized to receive either different dosages of the Tanezumab (an inhibitor of nerve growth factor) or a placebo, in order to determine the safety and efficacy of the Tanezumab treatment. The Tanezumab treatment group was observed to have reduced pain and improved function of the arthritic knee joint.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
